



REPORT ON A HUMAN PATCH TEST

48 hour closed patch test under occlusion

Skin test to evaluate potential skin irritation after contact with a cosmetic product

SYRPAS PANAGIOTIS

NATURAL MELISSOKOMIKI BEESWAX PROPOLIS

Farcoderm srl









SI.01.C_2015/2562			
20/10/2015			

INDEX

KEY PERSONNEL	pag. 3
STUDY DESIGN	pag. 4
Title	pag. 4
Aim of the study	pag. 4
Tested product	pag. 4
Ethical requirements	pag. 5
Subject selection	pag. 5
Materials and Methods	pag. 6
RESULTS	pag. 8
CONCLUSIONS	pag. 10
BIBLIOGRAPHY	pag. 11

Page 2 out of 11

Farcoderm srl







Record no :	SI.01.C_2015/2562
	20/10/2015

KEY PERSONNEL

Customer

SYRPAS PANAGIOTIS

Rodovolos Serron, 61041, GREECE

Experimenter

Dr.ssa Enza Cestone

Degree in Medicine and Surgery, Specialist in Dermatology and Venereology Consultant to Farcoderm s.r.l.

Quality Control

Dott.ssa Maria Luisa Ferrara **Biologist** Research - Farcoderm

Farcoderm Srl

Via Angelini, 21 27028 San Martino Siccomario (PV) tel. +39-0382 25504 - fax +39-0382 536006 Mail: information@farcoderm.com

Page 3 out of 11



Head Office: Piazzale Siena, 11 20146 Milan - ITALY Production site: Via Angelini, 21 27028 San Martino Siccomario (Pavia) - ITALY



+39 0382 25504 +39 0382 536006 information@farcoderm.com www.farcoderm.com PEC farcoderm@legalmail.it







SI.01.C_2015/2562		
20/10/2015		

STUDY DESIGN

Title

REPORT ON A HUMAN PATCH TEST
Skin test to evaluate potential skin irritation after contact with a cosmetic product.

Aim of the study

This study assesses the potential side effects (skin erythema and oedema reactions) that may occur after applying a cosmetic product to evaluate whether the topical product is safe for consumer use.

Tested Product

Information provided by the Customer

· Product name:

NATURAL MELISSOKOMIKI BEESWAX PROPOLIS

- The tested cosmetic product conforms to REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance) and to its annexes.
- Qualitative INCI formula: filed

Page 4 out of 11

Farcoderm srl







SI.01.C_2015/2562
20/10/2015

Ethical requirements

The study was carried out in compliance with the following ethical requirements:

- All of the subjects participating in the study are healthy volunteers at least 18 years old.
- All of the subjects participating in the study are selected under the supervision of a dermatologist according to inclusion/non inclusion criteria (see respective paragraph "Inclusion criteria" and "Non inclusion Criteria").
- Volunteer participation in the study is totally free.
- All of the subjects participating in the study are informed of the aim and the nature of the study.
- All of the subjects participating in the study are informed of the potential risks involved.
- All of the subjects participating in the study give their informed consent signed at the beginning of the study.
- Before volunteers were exposed to the product to be tested, all relevant safety information about the product itself and each ingredient were collected and evaluated.
- All of the study procedures are carried out in accordance with the ethical principles for the medical research (Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and successive amendments)
- All necessary precautions were taken to avoid adverse skin reactions.
- If unexpected/adverse skin reactions occur, the dermatologist evaluates the severity of the reaction (and report it in the data collecting sheet) and if necessary proceed with the appropriate therapy.

Subjects selection

Volunteers recruitment

25 volunteers were recruited to take a part in the test in accordance with the following inclusion and non inclusion criteria:

Inclusion criteria

- ☑ Male and female subjects
- ☑ Subjects between 18 and 70 years old
- ☑ Healthy subjects
- ☑ Subjects informed about test purposes

Non - inclusion criteria

- × Subjects who do not fit the inclusion criteria
- Pregnant or breastfeeding women
- Subjects with marks (for example tattoos, scars, burns) in the tested skin region, which might interfere with clinical evaluation
- Subjects with dermatological problems in the test area
- Subjects with medication which may affect skin response
- Subjects undergoing pharmacological treatment (both locally or systemically)
- Subjects with past history for contact dermatitis
- × Positive anamnesis for atopy

Withdrawal criteria

Partecipants are withdrawan if

- They do not follow the conditions of the Study Information Sheet that they receive after the recruitment
- They suffer any illnes or accident or develop any condition during the study which could affect the out come of the study
- They no longer wish to participate in the study.

Page 5 out of 11

Farcoderm srl









Record noti:	SI.01.C_2015/2562			
	20/10/2015			

Behaviour of volunteers during the test

Through patch application and 24 hours after patch removal volunteers must avoid situations or activity that could interfere with clinical evaluations:

- Exposition to sun or solarium
- × Sport activity
- Immersion in water or steam bath
- Chafing and mechanical or termal stress in the area in which patch is/has been applied.

Materials and Methods

Tested product and concentration

name sponsor concentration application method NATURAL MELISSOKOMIKI BEESWAX PROPOLIS
SYRPAS PANAGIOTIS
as it is

Sample preparation and application

The product is applied as it is by using the Finn Chamber, an 8 mm diameter aluminium disk. The Finn Chamber is fixed to the skin with a tape already been tested for its safety that ensure the occlusive application of the product. Applied quantity is sufficient to fill the chamber without overflowing from it when applied on the skin. The product is left in contact with the skin surface for 48 hours. The cutaneous reactions are analysed 15 minutes, one hour and 24 hours after Finn Chamber removal. A Finn Chamber containing a blotting paper disk soaked with demineralized water is applied and used as a negative control.

Clinical examination and scoring

Skin reactions are evaluated 15 minutes, 1 hour and 24 hours after patch removal according to the scores reported in table 1, that describes the severity of erythema, oedema or other types of skin irritation. The results are collected in a table and represented graphically. For each experimental time Mean Irritation Index (IIM) is calculated by adding erythema mean value and oedema mean value. The tested product is then classified following table 2 which is based on the Mean Irritation Index.

Page 6 out of 11

Farcoderm srl







SI.01.C_2015/2562
20/10/2015

Table 1 - Clinical score of skin reactions

No erythema	0
Light erythema (hardly visible)	1
Clearly visible erythema	2
Moderate erythema	3
Serious erythema (dark red with possible formation of light scars)	4
No oedema	0
Light oedema (hardly visible)	1
Light oedema	2
Moderate oedema (about 1 mm raised skin)	3
Strong oedema (extended swelling even beyond the application area)	4

Table 2 - Classification of the medium irritation index (according to the amended Draize classification).

Mean Irritation Index (IIM)	Product classification		
< 0,5	non irritating		
from 0.5 to 2.0	slightly irritating		
from 2.0 to 5.0	moderately irritating		
from 5.0 to 8.0	highly irritating		

Page 7 out of 11

Farcoderm srl







Rocard no. SI.01.C_2015/2562
date: 20/10/2015

RESULTS

Summary of the data obtained and evaluation of the product irritation potential

OEDEMA AND ERYTHEMA REACTIONS

	ID Vol	Sex	ERYTHEMA 15'	OEDEMA 15'	ERYTHEMA 1h	OEDEMA 1h	ERYTHEMA 24h	OEDEMA 24h
1	F0548M	F	0	0	0	0	0	0
2	B1438P	M	0	0	0	0	0	0
3	C1052D	M	0	0	0	0	0	0
4	S0872M	F	0	0	0	0	0	0
5	G1066R	F	0	0	0	0	0	0
6	R2408P	M	0	0	0	0	0	0
7	B1081G	F	0	0	0	0	0	0
8	L1763C	М	0	0	0	0	0	0
9	C0771F	F	0	0	0	0	0	0
10	Z2392D	М	0	0	0	0	0	0
11	C1934S	F	0	0	0	0	0	0
12	S1388A	F	0	0	0	0	0	0
13	R0446D	F	0	0	0	0	0	0
14	R0471E	F	0	0	0	0	0	0
15	F1946G	F	0	0	0	0	0	0
16 17	C1963A C2091G	F	0	0	0	0	0	0
18	G1390P	F F	0	0	0	0	0	0
19	S1258E	F	0	0	0	0	0	0
20	D1532C	F	0	0	0	0	0	0
21	M1965C	F	0	0	0	0	0	0
22	C1619M	F	0	0	0	0	0	0
23	S0869S	F	0		0	0	0	0
24	C1267R	F	0	0	0	0	0	0
25	B2463I	F	0	0	0	0	0	0

Farcoderm srl












Recard no SI.01.C_2015/2562
date: 20/10/2015

MEAN VALUES FOR OEDEMA AND ERYTHEMA





IRRITATION INDEX MEAN VALUES



Farcoderm srl

Head Office: Piazzale Siena, 11 20146 Milan - ITALY Production site: Via Angelini, 21 27028 San Martino Siccomario (Pavia) - ITALY +39 0382 25504
+39 0382 536006
information@farcoderm.com
www.farcoderm.com
PEC farcoderm@legalmail.it







SI.01.C_2015/2562 20/10/2015

CONCLUSIONS

The table and the graphs listed above contain the values of the erythema and oedema indices recorded for each volunteer. Potential skin irritation of the product has been assessed according to the amended Draize classification.

On the basis of the data obtained we deem the product:

SYRPAS PANAGIOTIS

NATURAL MELISSOKOMIKI BEESWAX PROPOLIS

NON IRRITATING

"DERMATOLOGICALLY TESTED"

S.Martino Siccomario - October, 20th 2015

Experimenter

DOTT. SSADESSAENZACESTONEONE

MEDICO CHIRURGO SPECIALISTA IN DERMATOLOGIA VENEREOLOGIA Via Cozz 6 - 27100 Part. TVA 0 2 3 4 1 1 1 PAVIA 10183 C.F. CST NZE 80647 M109Z Parere O.d.M. PV p. 32 del 03/11/2009

Quality control

Dott.ssa Maria Luisa Ferrara

Monottere

Page 10 out of 11

Farcoderm srl

Head Office: Piazzale Siena, 11 20146 Milan - ITALY Production site: Via Angelini, 21 27028 San Martino Siccomario (Pavia) - ITALY

+39 0382 25504 +39 0382 536006 information@farcoderm.com (1) www.farcoderm.com PEC farcoderm@legalmail.it







SI.01.C_2015/2562 20/10/2015

BIBLIOGRAPHY

Berger, R.S., and J.P. Bowman, 1982, "A Reappraisal of the 21-day Cumulative Irritation Test in Man," J. Toxicol. - Ot. & Ocular Toxicol., 1(2);109-115.

Holdiness, M.R., 1989, "A Review of Contact Dermatitis Associated with Transdermal Therapeutic Systems," Contact Dermatitis, 20(1):3-9.

Lanman, B.M., E.B. Elvers, and C.J. Howard, 1968, "The Role of Human Patch Testing in a Product Development Program," Joint Conference on Cosmetic Sciences, The Toilet Goods Association (currently, the Cosmetic, Toiletry and Fragrance Association), Washington, D.C., April 21-23, 1968.

Patel, S.M., E. Patrick, and H.I. Maibach, 1976, "Animal, Human, and In Vitro Test Methods for Predicting Skin Irritation," Dermatotoxicology, Chpt. 33, 5th Ed., Eds. F.N. Marzulli, H.I. Maibach, Taylor, and Frances.

Farcoderm srl

Head Office: Piazzale Siena, 11 20146 Milan - ITALY Production site: Via Angelini, 21 27028 San Martino Siccomario (Pavia) - ITALY





Page 11 out of 11



The result of the study reported in this document is only referred to the tested sample and the specific experimental conditions.

Any part of this report can only be reproduced with the consent of Farcoderm s.r.l.

A copy of this report is kept on file at Farcoderm s.r.l.

Both the informed consent and the information forms are kept on file at Farcoderm s.r.l. for 5 years after the date of issue of the report.